<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23150165</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1674-8018</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Protein &amp; cell</Title><ISOAbbreviation>Protein Cell</ISOAbbreviation></Journal><ArticleTitle>MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-&#x3bb;1.</ArticleTitle><Pagination><StartPage>130</StartPage><EndPage>141</EndPage><MedlinePgn>130-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13238-012-2081-y</ELocationID><Abstract><AbstractText>Interferon (IFN)-mediated pathways are a crucial part of the cellular response against viral infection. Type III IFNs, which include IFN-&#x3bb;1, 2 and 3, mediate antiviral responses similar to Type I IFNs via a distinct receptor complex. IFN-&#x3bb;1 is more effective than the other two members. Transcription of IFN-&#x3bb;1 requires activation of IRF3/7 and nuclear factor-kappa B (NF-&#x3ba;B), similar to the transcriptional mechanism of Type I IFNs. Using reporter assays, we discovered that viral infection induced both IFN-&#x3bb;1 promoter activity and that of the 3'-untranslated region (UTR), indicating that IFN-&#x3bb;1 expression is also regulated at the post-transcriptional level. After analysis with microRNA (miRNA) prediction programs and 3'UTR targeting site assays, the miRNA-548 family, including miR-548b-5p, miR-548c-5p, miR-548i, miR-548j, and miR-548n, was identified to target the 3'UTR of IFN-&#x3bb;1. Further study demonstrated that miRNA-548 mimics down-regulated the expression of IFN-&#x3bb;1. In contrast, their inhibitors, the complementary RNAs, enhanced the expression of IFN-&#x3bb;1 and IFN-stimulated genes. Furthermore, miRNA-548 mimics promoted infection by enterovirus-71 (EV71) and vesicular stomatitis virus (VSV), whereas their inhibitors significantly suppressed the replication of EV71 and VSV. Endogenous miRNA-548 levels were suppressed during viral infection. In conclusion, our results suggest that miRNA-548 regulates host antiviral response via direct targeting of IFN-&#x3bb;1, which may offer a potential candidate for antiviral therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yongkui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The State Key Laboratory of Virology and College of Life Sciences, Wuhan University, Wuhan 430072, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Jiajia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiupeng</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ao</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Yushun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Protein Cell</MedlineTA><NlmUniqueID>101532368</NlmUniqueID><ISSNLinking>1674-800X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000624353">interferon-lambda, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494232">IRF3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494234">IRF7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050838">Interferon Regulatory Factor-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050839">Interferon Regulatory Factor-7</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C561887">MIRN548 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>O84C90HH2L</RegistryNumber><NameOfSubstance UI="D011070">Poly I-C</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020413" MajorTopicYN="N">3' Untranslated Regions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019694" MajorTopicYN="N">Hepatitis B, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050838" MajorTopicYN="N">Interferon Regulatory Factor-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050839" MajorTopicYN="N">Interferon Regulatory Factor-7</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011070" MajorTopicYN="N">Poly I-C</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23150165</ArticleId><ArticleId IdType="pmc">PMC4875363</ArticleId><ArticleId IdType="doi">10.1007/s13238-012-2081-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida GM, de Oliveira DB, Magalhaes CL, Bonjardim CA, Ferreira PC, Kroon EG. Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus. Antiviral Res. 2008;80:302&#x2013;308. doi: 10.1016/j.antiviral.2008.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.06.016</ArticleId><ArticleId IdType="pubmed">18657576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006;80:4501&#x2013;4509. doi: 10.1128/JVI.80.9.4501-4509.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.80.9.4501-4509.2006</ArticleId><ArticleId IdType="pmc">PMC1472004</ArticleId><ArticleId IdType="pubmed">16611910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandi P, Pagliaccetti NE, Robek MD. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J Interferon Cytokine Res. 2010;30:123&#x2013;134. doi: 10.1089/jir.2009.0049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2009.0049</ArticleId><ArticleId IdType="pmc">PMC3096493</ArticleId><ArticleId IdType="pubmed">20038204</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281&#x2013;297. doi: 10.1016/S0092-8674(04)00045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00045-5</ArticleId><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001;75:7059&#x2013;7066. doi: 10.1128/JVI.75.15.7059-7066.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.15.7059-7066.2001</ArticleId><ArticleId IdType="pmc">PMC114434</ArticleId><ArticleId IdType="pubmed">11435586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33:e179. doi: 10.1093/nar/gni178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gni178</ArticleId><ArticleId IdType="pmc">PMC1292995</ArticleId><ArticleId IdType="pubmed">16314309</ArticleId></ArticleIdList></Reference><Reference><Citation>Conklin DC, Grant FJ, Rixon MW, Kindsvogel W. Interferon-&#x25b;. 2002.</Citation></Reference><Reference><Citation>Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004;18:504&#x2013;511. doi: 10.1101/gad.1184404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1184404</ArticleId><ArticleId IdType="pmc">PMC374233</ArticleId><ArticleId IdType="pubmed">15014042</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber JM. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci U S A. 1990;87:5238&#x2013;5242. doi: 10.1073/pnas.87.14.5238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.14.5238</ArticleId><ArticleId IdType="pmc">PMC54298</ArticleId><ArticleId IdType="pubmed">2115167</ArticleId></ArticleIdList></Reference><Reference><Citation>Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007;446:916&#x2013;920. doi: 10.1038/nature05732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05732</ArticleId><ArticleId IdType="pubmed">17392790</ArticleId></ArticleIdList></Reference><Reference><Citation>Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, Mello CC. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 2001;106:23&#x2013;34. doi: 10.1016/S0092-8674(01)00431-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(01)00431-7</ArticleId><ArticleId IdType="pubmed">11461699</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007;126:245&#x2013;249. doi: 10.1016/j.virusres.2007.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2007.03.006</ArticleId><ArticleId IdType="pubmed">17451832</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52:60&#x2013;70. doi: 10.1002/hep.23660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23660</ArticleId><ArticleId IdType="pubmed">20578129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001;293:834&#x2013;838. doi: 10.1126/science.1062961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1062961</ArticleId><ArticleId IdType="pubmed">11452083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297:2056&#x2013;2060. doi: 10.1126/science.1073827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1073827</ArticleId><ArticleId IdType="pubmed">12154197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y, He Y, Liu L, Zhong X. MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. FEBS Lett. 2010;584:961&#x2013;967. doi: 10.1016/j.febslet.2010.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2010.01.036</ArticleId><ArticleId IdType="pubmed">20100477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69&#x2013;77. doi: 10.1038/ni875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni875</ArticleId><ArticleId IdType="pubmed">12483210</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, et al. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001;276:39765&#x2013;39771. doi: 10.1074/jbc.M102502200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M102502200</ArticleId><ArticleId IdType="pubmed">11514542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415&#x2013;419. doi: 10.1038/nature01957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01957</ArticleId><ArticleId IdType="pubmed">14508493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Liu X, Ma Y, Sun Z, Yang Y, Jin Q, He B, Wang J. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J Virol. 2010;84:8051&#x2013;8061. doi: 10.1128/JVI.02491-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02491-09</ArticleId><ArticleId IdType="pmc">PMC2916543</ArticleId><ArticleId IdType="pubmed">20519382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Sun Z, Liu X, Jin Q, He B, Wang J. Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3. J Virol. 2011;85:8811&#x2013;8818. doi: 10.1128/JVI.00447-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00447-11</ArticleId><ArticleId IdType="pmc">PMC3165803</ArticleId><ArticleId IdType="pubmed">21697485</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A. 2005;102:17717&#x2013;17722. doi: 10.1073/pnas.0508531102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508531102</ArticleId><ArticleId IdType="pmc">PMC1308909</ArticleId><ArticleId IdType="pubmed">16301520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, Cheung WK, Chen S, Lu G, Wang Z, Xie D, Li K, Lin MC, Kung HF. Computational identification and characterization of primate-specific microRNAs in human genome. Comput Biol Chem. 2010;34:232&#x2013;241. doi: 10.1016/j.compbiolchem.2010.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiolchem.2010.08.001</ArticleId><ArticleId IdType="pubmed">20863765</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A. 2006;103:6001&#x2013;6006. doi: 10.1073/pnas.0601523103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0601523103</ArticleId><ArticleId IdType="pmc">PMC1458687</ArticleId><ArticleId IdType="pubmed">16585524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science. 2004;303:95&#x2013;98. doi: 10.1126/science.1090599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1090599</ArticleId><ArticleId IdType="pubmed">14631048</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008;7:1109&#x2013;1115. doi: 10.4161/cbt.7.7.6192.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cbt.7.7.6192</ArticleId><ArticleId IdType="pmc">PMC2435218</ArticleId><ArticleId IdType="pubmed">18698163</ArticleId></ArticleIdList></Reference><Reference><Citation>Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, Rice CM, Dustin LB. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology. 2011;54:1913&#x2013;1923. doi: 10.1002/hep.24580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24580</ArticleId><ArticleId IdType="pmc">PMC3219820</ArticleId><ArticleId IdType="pubmed">21800339</ArticleId></ArticleIdList></Reference><Reference><Citation>Milliken EL, Zhang X, Flask C, Duerk JL, MacDonald PN, Keri RA. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Lett. 2005;229:205&#x2013;215. doi: 10.1016/j.canlet.2005.06.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2005.06.044</ArticleId><ArticleId IdType="pmc">PMC1615916</ArticleId><ArticleId IdType="pubmed">16115727</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264:1918&#x2013;1921. doi: 10.1126/science.8009221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8009221</ArticleId><ArticleId IdType="pubmed">8009221</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol. 2007;179:3434&#x2013;3442. doi: 10.4049/jimmunol.179.6.3434.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.179.6.3434</ArticleId><ArticleId IdType="pubmed">17785777</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B. Hepatology. 2012. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581145</ArticleId><ArticleId IdType="pubmed">22706965</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquinelli C, Laur&#xe9; F, Chatenoud L, Beaurin G, Gazengel C, Bismuth H, Degos F, Tiollais P, Bach J, Br&#xe9;chot C. Hepatitis B virus DNA in mononuclear blood cells. A frequent event in hepatitis B surface antigen-positive and -negative patients with acute and chronic liver disease. J Hepatol. 1986;3:95&#x2013;103. doi: 10.1016/S0168-8278(86)80152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(86)80152-0</ArticleId><ArticleId IdType="pubmed">3018075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestka S. The human interferon-alpha species and hybrid proteins. Semin Oncol. 1997;24:S9-4&#x2013;S9-17.</Citation><ArticleIdList><ArticleId IdType="pubmed">9208870</ArticleId></ArticleIdList></Reference><Reference><Citation>Piriyapongsa J, Jordan IK. A family of human microRNA genes from miniature inverted-repeat transposable elements. PLoS One. 2007;2:e203. doi: 10.1371/journal.pone.0000203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0000203</ArticleId><ArticleId IdType="pmc">PMC1784062</ArticleId><ArticleId IdType="pubmed">17301878</ArticleId></ArticleIdList></Reference><Reference><Citation>Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005;79:3851&#x2013;3854. doi: 10.1128/JVI.79.6.3851-3854.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.6.3851-3854.2005</ArticleId><ArticleId IdType="pmc">PMC1075734</ArticleId><ArticleId IdType="pubmed">15731279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105:7034&#x2013;7039. doi: 10.1073/pnas.0707882105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0707882105</ArticleId><ArticleId IdType="pmc">PMC2383932</ArticleId><ArticleId IdType="pubmed">18467494</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Jonsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem. 2003;278:44312&#x2013;44319. doi: 10.1074/jbc.M307089200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M307089200</ArticleId><ArticleId IdType="pubmed">12952966</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63&#x2013;68. doi: 10.1038/ni873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni873</ArticleId><ArticleId IdType="pubmed">12469119</ArticleId></ArticleIdList></Reference><Reference><Citation>Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. 2005;174:1932&#x2013;1937. doi: 10.4049/jimmunol.174.4.1932.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.4.1932</ArticleId><ArticleId IdType="pubmed">15699120</ArticleId></ArticleIdList></Reference><Reference><Citation>Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, Spisni E, Pantaleo MA, Biasco G, Tomasi V. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res. 2009;315:1439&#x2013;1447. doi: 10.1016/j.yexcr.2008.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2008.12.010</ArticleId><ArticleId IdType="pubmed">19133256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Li Y, Mao A, Li C, Tien P. Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol. 2010;7:341&#x2013;348. doi: 10.1038/cmi.2010.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2010.36</ArticleId><ArticleId IdType="pmc">PMC4002683</ArticleId><ArticleId IdType="pubmed">20711230</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Liu Y, Mukhtar MM, Gong R, Pan Y, Rasool ST, Gao Y, Kang L, Hao Q, Peng G, et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS ONE. 2008;3:e1985. doi: 10.1371/journal.pone.0001985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001985</ArticleId><ArticleId IdType="pmc">PMC2288676</ArticleId><ArticleId IdType="pubmed">18414668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XY, Li YX, Li M, Zhang L, Feng LX, Zhang N. Cancer Lett. 2012. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer.</Citation><ArticleIdList><ArticleId IdType="pubmed">22776563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Gong R, Mu Y, Chen Y, Zhu C, Sun Z, Chen M, Liu Y, Zhu Y, Wu J. Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. J Immunol. 2011;187:4844&#x2013;4860. doi: 10.4049/jimmunol.1100998.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100998</ArticleId><ArticleId IdType="pubmed">21957142</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue X, Wang H, Zhao F, Liu S, Wu J, Ren W, Zhu Y. Hepatitis B virus-induced calreticulin protein is involved in IFN resistance. J Immunol. 2012;189:279&#x2013;286. doi: 10.4049/jimmunol.1103405.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103405</ArticleId><ArticleId IdType="pubmed">22661095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003;100:9779&#x2013;9784. doi: 10.1073/pnas.1630797100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1630797100</ArticleId><ArticleId IdType="pmc">PMC187842</ArticleId><ArticleId IdType="pubmed">12902540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>